Form 4: Armata Pharmaceuticals Executive Pierre Kyme Reports Stock Option Grant
SEC Form 4 Filing
Pierre Kyme, Chief Business Officer of Armata Pharmaceuticals, reports the acquisition of stock options.
Summary
- Pierre Kyme, Chief Business Officer of Armata Pharmaceuticals, filed a Form 4.
- The form reports the grant of stock options.
- Kyme acquired options to purchase 100,000 shares of common stock at an exercise price of $2.04.
- The options vest in four equal installments of 25% on February 5th of each of 2026, 2027, 2028 and 2029, subject to continuous service.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing related to executive compensation, which is neither particularly positive nor negative. It's a standard practice.
Positives
- The grant of stock options to the Chief Business Officer aligns his interests with those of the shareholders.
- The vesting schedule incentivizes continued service and contribution to the company's success.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management interests with those of shareholders.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Business Officer.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of the stock option grant. |
| 02/05/2026 | First vesting date for 25% of the stock options. |
| 02/05/2027 | Second vesting date for 25% of the stock options. |
| 02/05/2028 | Third vesting date for 25% of the stock options. |
| 02/05/2029 | Fourth vesting date for 25% of the stock options. |
| 02/05/2035 | Expiration date of the stock options. |
| 02/07/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.